- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
13 result(s) found for: Romidepsin.
Displaying page 1 of 1.
EudraCT Number: 2015-003186-28 | Sponsor Protocol Number: BPC01_002 | Start Date*: 2016-01-13 | |||||||||||
Sponsor Name:Bionor Pharma ASA | |||||||||||||
Full Title: BIOSKILL: Studying Vacc-4x, an HIV therapeutic vaccine, an assessment of immune-mediated anti-viral effects, when administered with adjuvant GM-CSF prior to HIV latent reservoir activation by the H... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005023-40 | Sponsor Protocol Number: RG_11-182 | Start Date*: 2013-05-22 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: ROMAZA: Phase I trial of combination therapy with romidepsin and azacitidine in patients with newly diagnosed, relapsed or refractory Acute Myeloid Leukaemia ineligible for conventional chemotherapy | |||||||||||||
Medical condition: Acute myeloid leukaemia (AML) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004747-23 | Sponsor Protocol Number: BPC01-001 | Start Date*: 2014-01-17 | |||||||||||
Sponsor Name:Bionor Pharma ASA | |||||||||||||
Full Title: An Open Phase I/IIa Study to Evaluate the Safety and Effect of Therapeutic HIV-1 Immunization using Vacc-4x + rhuGM-CSF, and HIV-1 Reactivation using Romidepsin, on the Viral Reservoir in Virologic... | |||||||||||||
Medical condition: HIV-infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001879-20 | Sponsor Protocol Number: RG_13-107 | Start Date*: 2013-12-30 | ||||||||||||||||
Sponsor Name:University of Birmingham | ||||||||||||||||||
Full Title: Phase I/II study to determine the maximum tolerated dose and activity of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma | ||||||||||||||||||
Medical condition: Peripheral T-cell Lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005238-23 | Sponsor Protocol Number: MCA-896 | Start Date*: 2016-10-18 | ||||||||||||||||
Sponsor Name:Rockefeller University | ||||||||||||||||||
Full Title: A phase 2a, randomized study of the combination of romidepsin and 3BNC117 to evaluate the effects on the HIV-1 reservoir (ROADMAP) | ||||||||||||||||||
Medical condition: HIV infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Prematurely Ended) DE (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023040-32 | Sponsor Protocol Number: ROMI-ADVM-004 | Start Date*: 2011-05-05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase IV, Open-Label, Single-Arm ROLLOVER STUDY FOR SUBJECTS WHO PARTICIPATED IN OTHER ROMIDEPSIN PROTOCOLS. Estudio de extensión de fase IV, abierto, de un solo brazo para pacientes que hayan p... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Rollover study supporting all indications from prior Romidepsin protocols eligible for participation in this study. Estudio de extensión que recoge todas las indicaciones de protocolos anteriores d... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: ES (Prematurely Ended) GB (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-001580-68 | Sponsor Protocol Number: Ro-CHOP_study | Start Date*: 2013-06-10 | |||||||||||
Sponsor Name:LYSARC | |||||||||||||
Full Title: Phase 3 Multi-Center Randomized Study to Compare Efficacy and Safety of Romidepsin¬ CHOP (Ro-CHOP) versus CHOP in subjects with Previously Untreated Peripheral T-Cell Lymphoma. | |||||||||||||
Medical condition: Peripheral T-Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Ongoing) IT (Completed) DE (Completed) PT (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005179-41 | Sponsor Protocol Number: FIL_PTCL13 | Start Date*: 2014-05-27 |
Sponsor Name:Fondazione Italiana Linfomi ONLUS (FIL-ONLUS) | ||
Full Title: ROMIDEPSIN IN COMBINATION WITH CHOEP AS FIRST LINE TREATMENT BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN YOUNG PATIENTS WITH NODAL PERIPHERAL T-CELL LYMPHOMAS: A PHASE I-II STUDY. | ||
Medical condition: Newly diagnosed patients with Peripheral T-cell lymphomas including: Peripheral T-cell lymphomas not otherwise specified (PTCL-NOS), Angioimmunoblastic T-cell lymphoma (AITL) and ALK– Anaplastic la... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2006-006228-21 | Sponsor Protocol Number: GPI-06-0002 | Start Date*: 2007-05-10 | |||||||||||
Sponsor Name:Gloucester Pharmaceuticals Inc. | |||||||||||||
Full Title: A PHASE II, MULTICENTER, OPEN-LABEL TRIAL EVALUATING THE ACTIVITY AND TOLERABILITY OF ROMIDEPSIN (DEPSIPEPTIDE, FK228) IN PROGRESSIVE OR RELAPSED PERIPHERAL T-CELL LYMPHOMA FOLLOWING PRIOR SYSTEM... | |||||||||||||
Medical condition: Progressive or relapsed Peripheral T-Cell Lymphoma (PTCL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) FR (Completed) ES (Completed) SE (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005157-23 | Sponsor Protocol Number: DART | Start Date*: 2013-05-21 | ||||||||||||||||||||||||||
Sponsor Name:Fondazione IRCCS Istituto Nazionale Tumori | ||||||||||||||||||||||||||||
Full Title: A Phase I/II Study of Danusertib in Combination with Romidepsin in Adult Patients with Mature Peripheral T Cell Lymphoma (PTCL) | ||||||||||||||||||||||||||||
Medical condition: (Ph I) Relapsed or refractory Hodgkin (HL) and Non Hodgkin lymphoma (NHL) in patients in the absence, unable ot who have been refused to undergo alternative salvage regimens. (Ph II) Relapsed or r... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-001625-40 | Sponsor Protocol Number: AX-CL-PANC-PI-008619 | Start Date*: 2019-10-21 | ||||||||||||||||||||||||||
Sponsor Name:GWT-TUD GmbH | ||||||||||||||||||||||||||||
Full Title: A MULTICENTER, PHASE I/II STUDY OF SEQUENTIAL EPIGENETIC AND IMMUNE TARGETING IN COMBINATION WITH NAB-PACLITAXEL/GEMCITABINE IN PATIENTS WITH ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA | ||||||||||||||||||||||||||||
Medical condition: Pancreatic Ductal Adenocarcinoma (PDAC) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002234-53 | Sponsor Protocol Number: eCLEAR-001 | Start Date*: 2016-11-14 | |||||||||||
Sponsor Name:Department of Infectious Diseases, Aarhus University Hospital | |||||||||||||
Full Title: Early administration of anti-latency reversing therapy and broadly neutralizing antibodies to limit the establishment of the HIV-1 reservoir during initiation of antiretroviral treatment - a random... | |||||||||||||
Medical condition: HIV persistence during initiation of antiretroviral therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001404-38 | Sponsor Protocol Number: FIL_GEMRO | Start Date*: 2012-07-12 | |||||||||||
Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS | |||||||||||||
Full Title: Phase IIa study on the role of Gemcitabine plus Romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. | |||||||||||||
Medical condition: Relapsed/refractory peripheral T-cell lymphoma patients. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
